DMRA Shorts Hold Firm as Activists Circle and Earnings Near

Damora Therapeutics heads into its November 4 earnings with two activists on its 13D register, a short position exceeding the entire free float, and retail attention running at a three-standard-deviation spike above its own 90-day history.

The short interest picture here is unlike almost anything in mid-cap biotech. Shorts hold the equivalent of 365% of DMRA's free float, a reading that reflects the small and tightly held nature of the float rather than a conventional crowded-short setup. The position has grown roughly 23% over the past month, though it barely moved on the week, down less than 0.2%. Borrow remains cheap at just over 2%, and availability has actually loosened this week to 176%, meaning roughly 1.75 shares are available to borrow for every share already shorted. That is a meaningful relaxation from the 52-week tightest reading of below 1% availability, and it tells a story of a market that is bearish but not yet scrambling for stock. With FINRA's most recent official count implying 4.8 days to cover and short interest sitting at 39% utilization of the lending pool, the borrow market looks well-supplied relative to demand.

What makes the ownership picture more interesting than the short register is the activist filings. Two holders carry Schedule 13D designations on the ORTEX EDGAR register: Fairmount Funds Management, which last disclosed a 19.99% stake in February 2026, and Novo Holdings, which previously reported 6.5% but whose most recent amendment, filed in October 2025, carries no percentage, meaning Novo may have exited below the 5% disclosure threshold without a further filing. Fairmount's unchanged declared stake makes it the dominant insider-aligned holder. Its shares also appear in the institutional table at 14.1% of shares, the second-largest institutional position behind FMR at nearly 15%. BlackRock filed a fresh 13G in July disclosing 5.1%, and JP Morgan Asset Management added 2 million shares as of August, a new position. Against this, Ikarian Capital cut from 21.5% to 0.6%, and both Jain Global and Point72 trimmed substantially. The activist disclosure caveat applies: these are as-last-filed positions, and holders below 5% need not refile.

The CEO bought in late September. Jennifer Jarrett purchased 12,500 shares at $20.23 on September 25, a discretionary open-market purchase worth just under $253,000, with no 10b5-1 plan declared. That is the only meaningful buy-sell signal in the insider record over the past 90 days, with net insider value across all transaction types reaching approximately $246,000 in that window. Given the stock closed at $20.67 on October 20, Jarrett's purchase is now marginally in the money following this week's 11% gain.

The ORTEX combined score of 73.5 reflects what appears to be mostly momentum. The stock has rallied 11% this week and 7% on Tuesday alone, though it remains down 8.5% over the past month and is well off its highs. Peer clinical-stage biotechs broadly participated in a wider sector bid this week: CTMX added 8%, ABVX gained 8.2%, and NRIX surged nearly 18%. DMRA's gain sits comfortably in the middle of that peer range. The short score factor rank of 8 places the stock in the bottom decile of its universe for short positioning, a persistent feature given the float structure. Price-to-book of 3.45 is the only valuation multiple with obvious meaning here, given the deeply negative earnings and EBITDA. The earnings yield is negative at -0.10.

The company's Wikipedia and ORTEX page traffic ran at a z-score of 3.4 relative to its own 90-day history, peaking in late September. That is a retail-attention spike worth noting as colour, though it carries no measured connection to clinical or financial outcomes. The drug-trials dataset from the US National Library of Medicine is being tracked, but no lead relationship to reported figures has been established.

The next print lands on November 4, two weeks out. Past earnings reactions for DMRA have been uniformly positive, with single and mid-single-digit gains on the day across the four most recent events. The more significant question heading in is whether Fairmount's disclosed 13D stake signals any coordination with management on the path toward the mid-2027 proof-of-concept readout for DMR-001, and whether the borrow market stays loose or tightens as the report date approaches.